Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivanib randomized discontinuation study in advanced tumors
NCT00633789Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2008
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of brivanib alaninate in non-small cell lung cancer (NSCLC), transitional cell carcinoma (TCC), soft tissue sarcoma (STS), gastric adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by Bristol Myers Squibb. Started Jun 2008; status: completed.
02
Drugs
brivanib alaninate
03
Conditions
non-small cell lung cancer (NSCLC)transitional cell carcinoma (TCC)soft tissue sarcoma (STS)gastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT00633789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00633789.